linagliptin Side Effects
Also known as: Tradjenta
Analysis of 17,378 adverse event reports submitted to the FDA from 2006 to 2025.
Total Reports
17,378
Death-Related
1,613
9.3% of reports
Hospitalizations
6,542
37.6% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 1,613 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 545 |
| ACUTE KIDNEY INJURY | 118 |
| RENAL FAILURE | 85 |
| PNEUMONIA | 83 |
| DYSPNOEA | 75 |
| OFF LABEL USE | 70 |
| DIARRHOEA | 61 |
| URINARY TRACT INFECTION | 60 |
| CARDIAC ARREST | 59 |
| SEPSIS | 56 |
| VOMITING | 56 |
| DECREASED APPETITE | 50 |
| CHRONIC KIDNEY DISEASE | 49 |
| CONDITION AGGRAVATED | 48 |
| FALL | 48 |
| CARDIAC FAILURE | 46 |
| CEREBROVASCULAR ACCIDENT | 46 |
| ASTHENIA | 43 |
| DISEASE PROGRESSION | 43 |
| CARDIAC FAILURE CONGESTIVE | 42 |
Reactions in Hospitalization Reports
Top reactions in 6,542 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| ACUTE KIDNEY INJURY | 543 |
| DYSPNOEA | 475 |
| DIARRHOEA | 442 |
| VOMITING | 402 |
| FATIGUE | 395 |
| OFF LABEL USE | 390 |
| FALL | 385 |
| PNEUMONIA | 380 |
| NAUSEA | 379 |
| PYREXIA | 351 |
| BLOOD GLUCOSE INCREASED | 325 |
| DIZZINESS | 320 |
| MALAISE | 306 |
| DEHYDRATION | 301 |
| ASTHENIA | 280 |
| RENAL FAILURE | 262 |
| URINARY TRACT INFECTION | 247 |
| CHEST PAIN | 234 |
| HYPOTENSION | 233 |
| HEADACHE | 226 |
Nearby — Related Medications
What the FAERS Data Reveals About linagliptin Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 17,378 voluntary reports linked to linagliptin and its brand equivalents (Tradjenta), spanning 2006 through 2025. Of those, 1,613 (9.3%) listed death as an outcome and 6,542 (37.6%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 51% were female and 49% male; age distribution skews toward 75+, with 4,362 reports in that bracket. The single most reported reaction is blood glucose increased with 1,326 submissions, followed by diarrhoea and nausea.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.